Quick Answer
LeonaBio, Inc. reported Net Income of -$105.61 million for fiscal year 2025.
LeonaBio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$105.61M -8.9% |
-$96.94M +17.6% |
-$117.67M -23.0% |
-$95.64M -74.4% |
-$54.85M -174.9% |
-$19.95M -286.6% |
| Diluted EPS | -$24.70 +1.9% |
-$25.19 -715.2% |
-$3.09 -22.1% |
-$2.53 -69.8% |
-$1.49 | — |
| Total Assets | $92.15M +56.8% |
$58.78M -63.3% |
$160.25M -37.9% |
$258.15M -22.2% |
$332.01M +18.8% |
$279.56M +12671.3% |
| Cash and Equivalents | $69.28M +43.0% |
$48.44M -46.5% |
$90.58M -5.6% |
$95.97M -13.2% |
$110.54M +82.3% |
$60.62M +2848.7% |
| Stockholders Equity | $27.79M -38.0% |
$44.84M -65.6% |
$130.19M -44.6% |
$235.14M -26.8% |
$321.08M +17.1% |
$274.28M +1490.7% |
| R&D Expense | $17.50M -75.2% |
$70.68M -24.6% |
$93.79M +52.6% |
$61.46M +43.6% |
$42.79M +222.1% |
$13.29M +250.3% |
| Operating Income | -$102.27M -1.4% |
-$100.90M +19.6% |
-$125.47M -20.6% |
-$104.02M -62.5% |
-$64.02M -220.2% |
-$20.00M -266.9% |
| Shares Outstanding | 9.34M +139.1% |
3.90M -89.8% |
38.17M +0.8% |
37.88M +1.3% |
37.38M +15.1% |
32.49M +792.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$6.61M | +77.0% | +5.1% |
| Diluted EPS | September 30, 2025 | -$1.68 | +77.5% | -833.3% |
| Total Assets | September 30, 2025 | $30.03M | -65.2% | -15.5% |
| Cash and Equivalents | September 30, 2025 | $20.87M | -69.7% | +5.0% |
| Stockholders Equity | September 30, 2025 | $26.79M | -53.5% | -16.3% |
| R&D Expense | September 30, 2025 | $2.83M | -84.2% | -22.8% |
| Operating Income | September 30, 2025 | -$6.87M | +76.8% | +5.7% |
| Shares Outstanding | September 30, 2025 | 3.94M | -89.8% | -90.0% |
- LeonaBio, Inc. reported Net Income of -$105.61 million for fiscal year 2025.
- LeonaBio, Inc. showed a decrease of -8.9% in Net Income compared to the prior fiscal year.
- LeonaBio, Inc. reported Diluted EPS of $24.70 per share (loss) for fiscal year 2025.
- LeonaBio, Inc. showed an increase of +1.9% in Diluted EPS compared to the prior fiscal year.
- LeonaBio, Inc. reported Total Assets of $92.15 million for fiscal year 2025.
- LeonaBio, Inc. showed an increase of +56.8% in Total Assets compared to the prior fiscal year.
- LeonaBio, Inc. reported Cash and Equivalents of $69.28 million for fiscal year 2025.
- LeonaBio, Inc. showed an increase of +43.0% in Cash and Equivalents compared to the prior fiscal year.
- LeonaBio, Inc. reported Stockholders Equity of $27.79 million for fiscal year 2025.
- LeonaBio, Inc. showed a decrease of -38.0% in Stockholders Equity compared to the prior fiscal year.
- LeonaBio, Inc. reported R&D Expense of $17.50 million for fiscal year 2025.
- LeonaBio, Inc. showed a decrease of -75.2% in R&D Expense compared to the prior fiscal year.
- LeonaBio, Inc. reported Operating Income of -$102.27 million for fiscal year 2025.
- LeonaBio, Inc. showed a decrease of -1.4% in Operating Income compared to the prior fiscal year.
- LeonaBio, Inc. reported Shares Outstanding of 9.34 million shares for fiscal year 2025.
- LeonaBio, Inc. showed an increase of +139.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: